{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:26:45Z","timestamp":1793914005070,"version":"4.8.0"},"reference-count":27,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203135\/Z\/16\/Z"],"award-info":[{"award-number":["203135\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>During the recent COVID-19 pandemic, reports of long-term persistence or recurrence of symptoms after SARS-CoV-2 infection emerged, which are now collectively referred to as \u2018long COVID\u2019. Most descriptions of long COVID originate from patients residing in high-income countries. We set out to characterise long COVID in a large-scale clinical trial that was conducted in low-middle, high-middle and high-income countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Anti-Coronavirus Therapies trials enrolled 6528 adult patients with symptomatic COVID-19 in Argentina, Brazil, Canada, Colombia, Ecuador, Egypt, India, Nepal, Pakistan, Philippines, Russia, Saudi Arabia, South Africa and the United Arab Emirates. Long COVID was defined as the presence of patient-reported symptoms at 180 days after enrolment. Multivariable logistic regression was used to evaluate associations of baseline characteristics with long COVID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 4697 included participants, 1181 (25.1%) reported long COVID symptoms. The most frequently reported symptoms were sleeping disorders (n=601; 12.8%), joint pain (n=461; 9.8%), fatigue (n=410; 8.7%) and headaches (n=382; 8.1%). Long COVID prevalence was higher in participants from lower middle-income compared with high-income countries (29.8% (850\/2854) vs 14.4% (102\/706); adjusted OR (aOR) 1.53 (1.10 to 2.14); p=0.012). Prevalence also varied between participants of different ethnic backgrounds and was highest (36.1% (775\/2145)) for patients of Arab\/North African ethnicity. Patients requiring inpatient admission were at increased risk of long COVID (aOR: 2.04 (1.63 to 2.54); p&lt;0.001). Other independent predictors of long COVID were male sex, older age and hypertension. Vaccination, prior lung disease, smoking and diabetes mellitus conferred protective effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Symptoms of long COVID are reported in a quarter of cases of symptomatic COVID-19 in this study and were significantly more prevalent in participants from countries with lower income status and in patients of Arab\/North African ethnicity. Research to further assess the health burden posed by long COVID in low- and middle-income countries is urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2024-017126","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:20:31Z","timestamp":1744734031000},"page":"e017126","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Long COVID prevalence and risk factors in adults residing in middle- and high-income countries: secondary analysis of the multinational Anti-Coronavirus Therapies (ACT) trials"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-5852","authenticated-orcid":false,"given":"Lucas Etienne","family":"Hermans","sequence":"first","affiliation":[{"name":"Internal Medicine, Groote Schuur Hospital, Cape Town, Western Cape, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[{"name":"Infection and Immunity Research Institute, St George\u2019s University of London, London, UK"},{"name":"Wellcome Discovery Research Platforms in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2025120721555746000_10.4.e017126.1","unstructured":"World Health Organization . A clinical case definition of post covid-19 condition by a delphi consensus. 2021."},{"key":"2025120721555746000_10.4.e017126.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01214-4"},{"key":"2025120721555746000_10.4.e017126.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43661-w","article-title":"True prevalence of long-COVID in a nationwide, population cohort study","volume":"14","author":"Hastie","year":"2023","journal-title":"Nat Commun"},{"key":"2025120721555746000_10.4.e017126.4","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.750378","article-title":"More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review","volume":"8","author":"Hayes","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025120721555746000_10.4.e017126.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005427","article-title":"Characterising long COVID: a living systematic review","volume":"6","author":"Michelen","year":"2021","journal-title":"BMJ Glob Health"},{"key":"2025120721555746000_10.4.e017126.6","doi-asserted-by":"crossref","unstructured":"Michelen M , Sigfrid L , Kartsonaki C , et al . Characterising long covid: a living systematic review update with controlled studies. medRxiv [Preprint]. doi:10.1101\/2022.08.29.22279338","DOI":"10.1101\/2022.08.29.22279338"},{"key":"2025120721555746000_10.4.e017126.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02116-3"},{"key":"2025120721555746000_10.4.e017126.8","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11020269","article-title":"Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms","volume":"11","author":"Han","year":"2022","journal-title":"Pathogens"},{"key":"2025120721555746000_10.4.e017126.9","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-022-01909-W"},{"key":"2025120721555746000_10.4.e017126.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24359","article-title":"Rates and Factors Associated With Documentation of Diagnostic Codes for Long COVID in the National Veterans Affairs Health Care System","volume":"5","author":"Ioannou","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025120721555746000_10.4.e017126.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000385","article-title":"Effect of covid-19 vaccination on long covid: systematic review","volume":"2","author":"Byambasuren","year":"2023","journal-title":"BMJ Med"},{"key":"2025120721555746000_10.4.e017126.12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.cjco.2022.02.010","article-title":"The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges","volume":"4","author":"Eikelboom","year":"2022","journal-title":"CJC Open"},{"key":"2025120721555746000_10.4.e017126.13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00299-5"},{"key":"2025120721555746000_10.4.e017126.14","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00298-3"},{"key":"2025120721555746000_10.4.e017126.15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad233","article-title":"Systematic Review of the Prevalence of Long COVID","volume":"10","author":"Woodrow","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025120721555746000_10.4.e017126.16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijregi.2023.08.004","article-title":"Burden, causation, and particularities of Long COVID in African populations: A rapid systematic review","volume":"8","author":"Nyasulu","year":"2023","journal-title":"IJID Reg"},{"key":"2025120721555746000_10.4.e017126.17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(23)01685-9","article-title":"Long COVID in low-income and middle-income countries: the hidden public health crisis","volume":"402","author":"Jassat","year":"2023","journal-title":"The Lancet"},{"key":"2025120721555746000_10.4.e017126.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12875-023-02196-1","article-title":"The cost of primary care consultations associated with long COVID in non-hospitalised adults: a retrospective cohort study using UK primary care data","volume":"24","author":"Tufts","year":"2023","journal-title":"BMC Prim Care"},{"key":"2025120721555746000_10.4.e017126.19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamainternmed.2023.0750","article-title":"Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis","volume":"183","author":"Tsampasian","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2025120721555746000_10.4.e017126.20","doi-asserted-by":"crossref","DOI":"10.1017\/S1463423622000585","article-title":"COVID-19 disease severity to predict persistent symptoms: a systematic review and meta-analysis","volume":"23","author":"Dirican","year":"2022","journal-title":"Prim Health Care Res Dev"},{"key":"2025120721555746000_10.4.e017126.21","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19010527","article-title":"Determinants of COVID-19-Related Length of Hospital Stays and Long COVID in Ghana: A Cross-Sectional Analysis","volume":"19","author":"Crankson","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025120721555746000_10.4.e017126.22","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00286-8"},{"key":"2025120721555746000_10.4.e017126.23","doi-asserted-by":"crossref","unstructured":"Galal I , Hussein AARM , Amin MT , et al . Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score. Egypt J Bronchol 2021;15. doi:10.1186\/s43168-020-00049-4","DOI":"10.1186\/s43168-020-00049-4"},{"key":"2025120721555746000_10.4.e017126.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260568","article-title":"Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up","volume":"16","author":"Tleyjeh","year":"2021","journal-title":"PLoS One"},{"key":"2025120721555746000_10.4.e017126.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02448-4","article-title":"Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12\u2009months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID)","volume":"20","author":"Pazukhina","year":"2022","journal-title":"BMC Med"},{"key":"2025120721555746000_10.4.e017126.26","doi-asserted-by":"crossref","unstructured":"Kisiel MA , Janols H , Nordqvist T , et al . Predictors of post-COVID-19 and the impact of persistent symptoms in non-hospitalized patients 12 months after COVID-19, with a focus on work ability. Ups J Med Sci 2022;127. doi:10.48101\/ujms.v127.8794","DOI":"10.48101\/ujms.v127.8794"},{"key":"2025120721555746000_10.4.e017126.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01145-2"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-017126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:56:07Z","timestamp":1765173367000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-017126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjgh-2024-017126"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-017126","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}